Before Invest
AbbVie Inc. logo

AbbVie Inc.

ABBV
Pharmaceutical Preparations
Last filing · Quarter 2 · Jun 30, 2026
Financial Statements Ratios
Export XLSX
Unlock 10 years
Statement
Period
Annual Quarterly
Order
Format
% Change
Rows
USD ($)
$ in Millions, shares in Millions		LTMDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016Dec 31, 2015Dec 31, 2014Dec 31, 2013
Net revenues
$ 64,386
$ 61,160
$ 56,334
$ 54,318
Cost of products sold
18,365
18,204
16,904
20,415
Selling, general and administrative
14,674
14,010
14,752
12,872
Research and development
9,714
9,096
12,791
7,675
Acquired IPR&D and milestones
4,980
5,016
2,757
778
Other operating income
217
241
7
179
Other expenses
-
-
-
-
Total operating costs and expenses
47,516
46,085
47,197
41,561
Operating earnings
16,870
15,075
9,137
12,757
Interest expense, net
(2,646)
(2,627)
(2,160)
(1,684)
Net foreign exchange loss
-
(58)
(21)
(146)
Other expense, net
(5,494)
(5,793)
(3,240)
(4,677)
Earnings before income tax expense
8,699
6,597
3,716
6,250
Income tax expense (benefit)
2,383
2,364
(570)
1,377
Net earnings
6,316
4,233
4,286
4,873
Net earnings attributable to noncontrolling interest
6
7
8
10
Net earnings attributable to AbbVie Inc.
$ 6,310
$ 4,226
$ 4,278
$ 4,863
Per share data
              
Basic earnings per share (in dollars per share)
$ 3.54
$ 2.37
$ 2.4
$ 2.73
Diluted earnings per share (in dollars per share)
3.54
2.36
2.39
2.72
Cash dividends declared per common share (in dollars per share)
-
-
-
-
Weighted-average basic shares outstanding (in shares)
1,769
1,769
1,769
1,768
Weighted-average diluted shares outstanding (in shares)
1,773
1,773
1,773
1,773